Bridge Biotherapeutics, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Seongnam Korea, Republic of (2015)

Organization Overview

First Clinical Trial
2018
NCT03482648
First Marketed Drug
2021
alxn1101
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Bridge Biotherapeutics, Inc. | ORIGIN | VP Clinical Development, CoA Therapeutics, Inc., a Bridgebio company

Active Ingredients

Marketed Drugs (1)

alxn1101 (2021)

Drugs in Phase 3 Trials (1)

Key: Bridge Biotherapeutics, Inc. (0) Acquired (1)

ag10 (8 trials)

Drugs in Phase 2 Trials (4)

Key: Bridge Biotherapeutics, Inc. (3) Acquired (1)

bbt-176 (1 trial)

bbt-401-1s (3 trials)

cetuximab (erbitux) (1 trial)

ferumoxides (feridex I.V.) (1 trial)

Drugs in Phase 1 Trials (5)

bbp-671 (1 trial)

bbt-877 (3 trials)

esomeprazole (nexium) (1 trial)

itraconazole (sporanox) (1 trial)

midazolam (versed) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 1)

Pulmonary Fibrosis (Phase 1)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 17
  • # of Trial APIs: 10